Amgen's BLA761298 for PAVBLU Receives AP Status from FDA
The FDA has granted application BLA761298 for PAVBLU an Approval Pending (AP) status.
Company
Pharmaceutical intelligence for Amgen with 22 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.